/stocks — the workspaceLOADING
Maze Therapeutics, Inc. (MAZE) is a biological products, (no diagnostic substances) company. 19 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-08-11 from MAZE's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
A plain-English read on MAZE plus an auto-SWOT — built from MAZE's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate MAZE using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
| Coloma Jason VChief Executive Officer | SELL | $1.0M | view → |
| Bernstein HaroldPresident, R&D & CMO | SELL | $437K | view → |
| Dandekar AtulCSBO | SELL | $210K | view → |
| Coloma Jason VChief Executive Officer | SELL | $725K | view → |
| Bernstein HaroldPresident, R&D & CMO | SELL | $381K | view → |
| Coloma Jason VChief Executive Officer | SELL | $174K | view → |
| Dandekar AtulCSBO | SELL | $198K | view → |
| Coloma Jason VChief Executive Officer | SELL | $847K | view → |
Projected from MAZE's own SEC 8-K filing history — the year-over-year reporting pattern (~50% land the exact day, ~90% within a week). No analyst estimates, no scraped calendars, nothing invented. It upgrades to a confirmed date + time the moment MAZE files its announcement.
MAZE has sold off after 4 of its last 6 earnings reports.
Large earnings reactions have been common.
MAZE has traded lower after most recent earnings releases.
The average is inflated by its most volatile prints (+5.6% and -35.3%).
A more typical earnings reaction has been approximately ±5.9%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-05-12 | +5.6% |
| 2026-03-25 | -35.3% |
| 2025-11-06 | -5.5% |
| 2025-08-12 | +1.0% |
| 2025-05-14 | -6.2% |
| 2025-03-31 | -13.3% |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.